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Abstract
Introduction: Detection of serum biomarkers for early diagnosis of breast cancer remains an important goal.
Changes in the structure of O-linked glycans occur in all breast cancers resulting in the expression of glycoproteins
that are antigenically distinct. Indeed, the serum assay widely used for monitoring disease progression in breast
cancer (CA15.3), detects a glycoprotein (MUC1), but elevated levels of the antigen cannot be detected in early
stage patients. However, since the immune system acts to amplify the antigenic signal, antibodies can be detected
in sera long before the antigen. We have exploited the change in O-glycosylation to measure autoantibody
responses to cancer-associated glycoforms of MUC1 in sera from early stage breast cancer patients.
Methods: We used a microarray platform of 60mer MUC1 glycopeptides, to confirm the presence of
autoantibodies to cancer associated glycoforms of MUC1 in a proportion of early breast cancer patients (54/198).
Five positive sera were selected for detailed definition of the reactive epitopes using on chip glycosylation
technology and a panel of glycopeptides based on a single MUC1 tandem repeat carrying specific glycans at
specific sites. Based on these results, larger amounts of an extended repertoire of defined MUC1 glycopeptides
were synthesised, printed on microarrays, and screened with sera from a large cohort of breast cancer patients (n
= 395), patients with benign breast disease (n = 108) and healthy controls (n = 99). All sera were collected in the
1970s and 1980s and complete clinical follow-up of breast cancer patients is available.
Results: The presence and level of autoantibodies was significantly higher in the sera from cancer patients
compared with the controls, and a highly significant correlation with age was observed. High levels of a subset of
autoantibodies to the core3MUC1 (GlcNAcb1-3GalNAc-MUC1) and STnMUC1 (NeuAca2,6GalNAc-MUC1) glycoforms
were significantly associated with reduced incidence and increased time to metastasis.
Conclusions: Autoantibodies to specific cancer associated glycoforms of MUC1 are found more frequently and at
higher levels in early stage breast cancer patients than in women with benign breast disease or healthy women.
Association of strong antibody response with reduced rate and delay in metastases suggests that autoantibodies
can affect disease progression.
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Studies investigating the role of cancer associated anti-
gens in the diagnosis of malignancy, and in cancer pro-
gression have focused on the MUC1 antigen, which is
expressed in an aberrantly glycosylated form in most
carcinomas including breast cancer [1-4]. Assays to
detect the cancer-associated antigen in serum (for exam-
ple, the CA15.3 assay) are widely used for monitoring
disease progression and response to therapy in some
late stage breast cancer patients, but this assay does not
detect elevated levels of MUC1 in serum from patients
with early stage disease [5]. The detection of biomarkers
in serum that could diagnose the presence of breast can-
cer, therefore, remains an important goal.
In contrast to antigens, autoantibodies can be detected
in serum from early stage patients, the immune system
serving to amplify the detection of antigen [6-10]. Most
of the studies to date analyzing the profile of antibodies
to MUC1 have used ELISA assays, generally detecting
all Ig antibodies to the unglycosylated form of the
mucin, or undefined glycoforms [1-3,11,12]. We have
developed a novel O-glycopeptide array-based assay
detecting IgG autoantibodies to specific glycoforms of
MUC1 [13], which has low backgrounds and detects
autoantibodies in sera from cancer patients. Our
approach utilizes the added dimension of the changes in
O-glycosylation that occur in cancer. This is in contrast
to other methods used to identify specific targets for
autoantibodies that do not allow for the detection of
antibodies to epitopes resulting from cancer-associated
post-translational modifications [1,10,14].
The pattern of O-glycosylation of membrane or
secreted glycoproteins is consistently altered in virtually
all cancers. In this type of glycosylation a family of poly-
peptide GalNAc-transferases add the sugar N-acetylga-
lactosamine (GalNAc) to serine and threonine residues
i nt h ec o r ep r o t e i n ,a n dt h eg l y c a nc h a i ni se x t e n d e db y
adding other sugars, individually and sequentially in the
Golgi pathway. Chain termination occurs by adding spe-
cific sugars such as sialic acid or fucose [15]. In breast
cancer, glycan chains can be terminated early, in part
due to changes in the expression of some glycosyltrans-
ferases [16], resulting in the expression of novel glyco-
peptide epitopes, which alter the immunogenicity of the
glycoprotein [17,18]. In the case of mucin glycoproteins,
because of the presence of multiple tandem repeats
which are rich in serine and threonine, the protein car-
ries hundreds or even thousands of O-glycans, and
changes in their composition can dramatically affect the
immunogenicity of the cancer-associated glycoform.
MUC1 is the most widely expressed of the mucins,
being found to some degree in epithelia lining glands or
ducts. It is, however, upregulated in breast and other
carcinomas as well as being differently glycosylated [16].
The tandem repeat sequence in MUC1 is composed of
20 amino acids (VTSAPDTRPAPGSTAPPAHG) within
which there are five potential O-linked glycosylation
sites (serines and threonines), and the number of tan-
dem repeats varies between 25 and 125 depending on
the allele. The truncated glycans carried on breast can-
cer-associated MUC1 include the single sugar, aGalNAc
(Tn), its sialylated derivative (STn), T (Galb1,3GalNAca)
and sialylated T (see Figure 1). Our initial pilot studies
used an array of 60mer MUC1 glycopeptides carrying
various truncated glycans (enzymatically synthesized on
the peptide in solution) for the detection of autoantibo-
dies in a small number of breast cancer patients [13].
While antibodies to both Tn and STn MUC1 glycopep-
tides were detected in some patients, a more frequent
antibody response was seen to MUC1 carrying a trun-
cated core3 glycan (GlcNAcb1-3GalNAca).
We have recently demonstrated a novel method of on-
chip synthesis of 20mer MUC1 glycoproteins to explore
in detail the positions of the O-glycans attached to the
MUC1 peptide in the glycopeptides eliciting an autoan-
tibody response [19]. Based on the initial analysis, and
work presented here using on-chip synthesis, corre-
sponding glycopeptides and additional glycoforms were
selected for preparative scale synthesis in order to ana-
lyze antibody responses in a large cohort (395 serum
samples) of breast cancer patients with Stage I or Stage
II disease, comparing the autoantibody response to that
in sera from patients with benign disease or age-
matched healthy females. As with the pilot study, we
find that the dominant antibody responses were to the
MUC1 carrying the truncated core3 and STn glycans.
The analysis of autoantibodies to MUC1 glycoforms
demonstrated an autoantibody response in early stage
breast cancer patients that is highly significantly related
to age, emphasizing the importance of using age matched
controls in screening. Moreover, autoantibodies to specifc
glycoforms of MUC1 were detected more frequently and
at a higher level in breast cancer patients than in patients
with benign breast disease or healthy females. Interest-
ingly, autoantibody induction to the core3 based and STn
glycoforms of MUC1 is significantly related to a lower
incidence of metastases and increased time to metastasis,
suggesting that autoantibodies to cancer-associated glyco-
forms of MUC1 may play a role in the development and
progression of the disease.
Materials and methods
Construction and quality control of glycopeptide micro-
arrays
Microarrays with glycopeptides extended from Tn
MUC1 glycopeptides on-chip used for epitope map-
ping Thirty-one Tn glycopeptides (each carrying one to
five glycans) were chemically synthesized and extended
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Figure 1 O-linked glycosylation in breast cancer and normal mammary gland and informative glycopeptides used. A, aberrant O-linked
glycosylation results in the expression of Tn, STn, Core 1 and ST glycoforms, left of the dotted line. O-glycans in the normal mammary gland are
mostly core2 based, right bottom. Note: core3 based glycans (top right) have not been demonstrated in the normal or malignant breast.
B, Sequence of MUC1a and MUC1b showing sites of glycosylation and glycans carried.
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NAcI for STn synthesis and the core3 b1-3 GlcNAc
transferase for the synthesis of core3MUC1 glycopep-
tides. Five breast cancer sera selected as having antibo-
dies to core3 MUC1 and/or STn MUC1, on the 60mer
arrays, were screened on these arrays of MUC1 mono-
mer glycopeptides.
Arrays for screening of the large cohorts of breast can-
cer patients (n = 395), patients with benign breast
disease (n = 108) and healthy women (n = 99) The
Tn-MUC1a, Tn-MUC1b, Core3-MUC1a and Core3-
MUC1b glycopeptides were generously provided by Gly-
coZym Inc. (Beverly, MA, USA). and further elongated
enzymatically in solution. Briefly, general enzymatic
Figure 2 Epitope mapping of autoantibodies in sera from breast cancer patients. Arrays were produced by on-slide glycosylation of the
MUC1a glycopeptides carrying Tn at the sites indicated in red using core3 b3GlcNAc-T6 (middle panel) and ST6GalNAc-I (right panel). The arrays
were stained with diluted sera (1:20) and Cy3 labelled anti-human-IgG. A, B, C show data obtained with sera from three individual patients.
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peptide) were performed with one or several recombi-
nant glycosyltransferases, T-synthase dC1GalT1
Drosophila melanogaster [17], b3Gal-TV [20], ST3GalI
[20] and ST6GalNAcI [17] together with the corre-
sponding donor sugar nucleotides (5 mM) in sodium
cacodylate buffer solution (2.0 mL, 0.5 M, pH 7.2) con-
taining manganese(II)chloride and incubated at room
temperature for 24 hrs. All glycopeptides synthesised in
solution, were individually diluted with water (1 mL),
a n ds l o w l yp a s s e dt h r o u g haC - 1 8I s o l u t ec a r t r i d g e( 0 . 5
g, previously washed with 5 mL of MeOH followed by
20 mL of water). After washing the column with water
(10 mL), the desired material was eluted with a stepwise
gradient (0 to 90% MeOH:water (0.5 mL aliquots). All
fractions were analyzed by MALDI-TOF and fractions
containing the desired product were pooled and lyophi-
lized. Recombinant MUC1 based glycoproteins carrying
ST and T were produced in CHOK1 cells as described
by Bäckström et al. [21] and those without O-linked gly-
cans or carrying the Tn glycan were produced in CHO
ldlD cells. Glycopeptides and glycoproteins were used
for printing of 48-well slides (for list of glycopeptides,
see Table S1 in Additional file 1).
Printing of slides
Printing was performed on Schott Nexterion
® Slide H,
Schott Nexterion
®. Slide H MPX16 or MPX48 (Schott
AG, Mainz, Germany). All salts for all the buffers,
including TES, Triton-X-100 Tween 20, and ethanola-
mine were from Merck (Whitehouse Station, NJ, USA).
Printing of the 48-well microarray slides was performed
using a BioRobotics MicroGrid II spotter (Genomics
Solution, Huntingdon, Cambridgeshire, UK) using
Stealth 3B Micro Spotting Pins (Telechem International
ArrayIt Division, Sunnyvale, CA, USA). The compounds
were distributed into 384-well source plates (BD Falcon
Microtest™ from BD Biosciences, Le Pont De Claix,
France), 20 μL per well at 100 μM final concentration
diluted in print buffer (PB) (150 mM phosphate, 0.005%
CHAPS pH 8.5). The MPX16 well slides were printed in
quadruplicates using an 8-pin (8 × 2) configuration
within a 28 × 28 subgrid at a 0.20 mm pitch between
each spot, and the MPX48 well slides were printed in
three replicates using an 24-pin (6 × 4) configuration
within a 12 × 12 subgrid at a 0.15 mm pitch between
each spot. The pin dwell time in the wells was four sec-
onds and the pins underwent three wash cycles in
between source plate visits. The complete 8 × 2 or 6 ×
4 array pattern was printed on a 16-well or 48-well slide
in duplicate respectively. Scanning of the slides was per-
formed on ProScanArray HT Microarray Scanner (Per-
kinElmer, Cambridge, Cambridgeshire, UK) followed by
image analysis with ProScanArray Express 4.0 software
(PerkinElmer). Human IgG was spotted (100 ug/mL in
PB) for control of second antibody reactivity and for
orientation of the scanned slides. Data were analyzed
and plotted using Microsoft
® Excel, GraphPad Prism
software or MathWorks Matlab software (Microsoft
®,
Reading, Berkshire, UK). Quality control of printed gly-
copeptides were visualized by staining with glycoform-
specific lectins and antibodies as described [13,19] (see
Figure S1 in Additional file 2).
Sera collection
The sera from cancer patients used in this study are
part of a series of consecutive Stage I and Stage II breast
cancer patients collected at Guy’sH o s p i t a l ,L o n d o n
between 1975 and 1980, known as the P-series. A total
of 400 sera were randomly selected of which 5 did not
fit the criteria and were, therefore, excluded leaving a
cohort of 395. Complete clinical follow-up is available
for these patients. The mean age of the cancer patients
at the time of collection (one day pre-surgery) was 59.9
years, see Table 1 for clinical and treatment parameters
of this cohort. Sera were taken with informed patient
consent for the study of prognostic markers and were
not taken as part of a particular clinical trial. At the
time of taking these samples written informed consent
was not required nor was ethnicity recorded. Ethical
approval for use of the samples in the present study was
obtained from the Outer South East London Research
Ethics Committee, REC reference 07/H0809/51. Sera
were also collected from 108 patients with benign breast
disease who attended Guy’s Hospital during the same
period. Benign breast disease ranged from breast pain to
benign tumours such as fibroadenomas. The mean age
of the benign patients at the time of sera collection was
45 years. Sera from 99 healthy volunteer females living
on the island of Guernsey formed the normal cohort
(mean age 54.7) [22]. Sera were taken from these
women between 1977 and 1985. The women who
donated these control sera were followed-up for
between 25 and 30 years and at the time of sera selec-
tion (end of 2008) all except three were still alive and
cancer free. However, none of the three that died had
been diagnosed with cancer and one died in 2003 aged
102 and two in 2000 aged 93 and 95. Written informed
consent had been obtained from each volunteer. This
consent covered use of the serum for the investigations
into the discovery of cancer biomarkers and access to
the womens’ medical records. Ethical approval to allow
the access to patients’ medical records of the volunteers
who donated sera to the Guernsey bank has been
obtained from the Guernsey and Alderney Committee.
All blood samples were treated in an identical manner.
Blood was allowed to clot, spun and the serum removed
and aliquoted before storing at -20°C.
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Microarray slides were blocked in 50 mM ethanolamine
in sodium borate buffer pH 8.5 at room temperature for
one hour with gentle agitation. Slides were washed three
times with PBS (phosphate buffered saline; 0.5M
Na2HPO4, 0.15M NaCl, 0.3M KCl, 0.5M KH2PO4,p H
7.4), rinsed in MilliQ water and dried by centrifugation
(Labnet, Oakland, Rutland, UK), C1303-T-230V-UK,
4 , 8 0 0r p m ) .2 5u l( M P X 1 6w e l ls l i d e s )o r5u L( M P X 4 8
well slides) of serum diluted (1:25 in 1 × PLI-P Buffer,
0.0065M Na2HPO4, 0.5M NaCl, 0.003M KCl, 0.0015M
KH2PO4, 1% BSA, 1% Triton-X-100, pH 7.4) was added
to each well and the slides incubated at room tempera-
ture for one hour with gentle agitation. Slides were
washed with PBS wash buffer (PBS containing 0.05%
Tween-20) and then with PBS, and then probed with
Cy3 labelled anti-human IgG secondary antibody
(1:1,000 dilution, C2571 Sigma, Gillingham, Dorset, UK)
at room temperature, for one hour, with gentle agita-
tion. Slides were then washed again and scanned with a
single laser power and detector gain setting. The images
were quantified with ProScanArray Express software
program (PerkinElmer). Spots were identified using
automated spot finding or manual adjustments for occa-
sional irregularities. The spot intensities were deter-
mined by subtracting the median compound for each
sample. The operator was blinded as to which samples
were from breast cancer patients or controls and all
samples were screened in duplicate with the same posi-
tive control serum from a breast cancer patient being
r u no ne v e r ys l i d e .T h er e p r o d u c i b i l i t yo ft h ea s s a yw a s
assessed by screening a subset of samples at two sites
(KCL and University of Copenhagen). A total of 57 sam-
ples from cancer patients were assessed as positive in
Copenhagen and 55 of these were positive in the screen
at KCL indicating 96% agreement.
Data analysis
Determination of positive sera
Each glycoform of MUC1 was synthesised on two over-
lapping peptides known as MUC1a and MUC1b (see
above and Figure 1). The combination of MUC1a and
MUC1b carrying one type of glycan is defined as the
feature. Sera were defined as being positive if they
reacted with one or both of the MUC1a and MUC1b
glycopeptides that carried the same glycan, taking the
Table 1 Distribution of clinical, treatment and outcome
parameters of 395 early breast cancer patients
Parameters Early stage breast cancer,
total number cases = 395. n (%)
Age at diagnosis
<50 63 (16)
50 to 59 132 (34)
60 to 69 136 (34)
70+ 64 (16)
Stage
Node negative 200 (51)
Node positive 193 (49)
nk 2
Positive nodes
0 200 (51)
1 to 3 124 (32)
4+ 69 (17)
nk 2
Clin tumour size
0 to 2 cm 133 (35)
2.1 to 4 cm 176 (46)
>4 cm 74 (19)
nk 16
Tumour type
Infiltrating ductal 338 (88)
Infiltrating lobular 34 (9)
Other 10 (3)
nk 13
ER Status
ER negative 131 (38)
ER positive 211 (62)
nk 53
Parity
0 children 87 (25)
1 to 2 children 171 (48)
3+ children 96 (27)
nk 41
Type of surgery
Radical mastectomy 372 (94)
Simple mastectomy 16 (4)
Wide local excision 6 (2)
nk 1
Adjuvant radiotherapy
Yes 23 (6)
No 372 (94)
Adjuvant chemotherapy
Yes 65 (16)
No 330 (84)
Adjuvant tamoxifen
Yes 20 (5)
No 375 (95)
Metastases to 15 yrs
Yes 155 (39)
No 238 (61)
Table 1 Distribution of clinical, treatment and outcome
parameters of 395 early breast cancer patients
(Continued)
Deaths to 15 yrs
Dead 219 (55)
Alive 176 (45)
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defined as being two standard deviations (SDs) above
the mean of the reactivity of sera from patients with
benign breast disease or healthy female controls, on the
corresponding feature. A strong positive was defined as
being four SDs above the means. These cut offs were
chosen as the data are close to a half-normal distribu-
t i o na n di tw o u l d ,t h e r e f o r e ,b ee x p e c t e dt h a ta tl e a s t
95% of the data to be below +2 SDs. After sample analy-
sis and image processing a data set was constructed.
Chi-squared tests were used to determine the P-values
in Tables 2 and 3.
ROC curve analysis
The sensitivity and specificity for every possible thresh-
old decision rule was calculated to plot a receiving
operational characteristic (ROC) curve for a single fea-
ture. Such a decision rule for a feature with value x
w o u l dt a k et h ef o l l o w i n gf o r m( i nt h i se x a m p l ew ew i l l
use benign vs malignant):
prediction =

Breast Cancer if x  θ
Benign if x < θ
for a preselected threshold θ.
The generalised ROC was formed by finding a linear
combination of features which gives the largest area
under the ROC curve. The features, xi ,f o ri = 1,...,k for
k number features are combined into one `general’ fea-
ture, z,b y
z =
k 
i=1
wixi
where w1,...,wk are the weights for each feature which
were set to 1 to reflect the fact that we did not have
pre-disposition towards a particular feature. Also, we
did not perform any model selection in order to fine-
tune the best combination of weights: This was to avoid
any data snooping inherent with such an approach.
Statistical tests used for clinical analyses
Comparisons of the distribution of positive status with
clinical parameters were made using the Chi-squared
test of significance. Comparisons of metastasis-free
survival by positive status were made using the Kaplan
Meier Log Rank test and Cox Proportional Hazards
models were used for the multivariate analysis. These
tests were performed using the SPSS (v.16) statistical
package (IBM, Feltham, Middlesex, UK).
Quantitative real-time-PCR
Frozen tissues (0.5 mm
3)f r o m5 8p r i m a r yb r e a s t
tumours, showing more than 70% tumour were crushed
to powder using a Mikrodismembrator II (Sartorius)
and lysed in Qiazol (Qiagen, Crawley, West Sussex,
UK). Total RNA was extracted using the RNEasy Lipid
tissue kit (Qiagen) according to manufacturer’si n s t r u c -
tions. The integrity of the extracted RNA was controlled
using a Bioanalyser (Agilent, Wokingham, Berkshire,
UK). DNased RNA (2 μg) was reverse transcribed using
random hexamer primers and superscript III reverse
transcriptase (Invitrogen, Paisley, Scotland, UK). QRT-
PCR was performed using the Opticon qRT-PCR analy-
sis system (Biorad, Hemel Hempstaed, Hertfordshire,
UK), a hot-start PCR reaction that contained the ds-spe-
cific DNA-binding dye SYBR Green I (Sigma), and 100
pmol of the forward and reverse primers shown:
ACTB forward primer 5’ CCCTCCATCGTCCACCG-
CAAATGCTTC 3’:
ACTB reverse primer 5’ CGACTGCTGTCACCTT-
CACCGTTCCAG 3’
B3GNT6 forward primer 5’CGGCTAGACTATC
TCTTCATCCTC3’
B3GNT6 reverse primer 5’CCACTCACTTGTAA
ACAGTGGAAA3’
C1GALT1 forward primer 5’GAGGTGGCTTCTTT
CAAAATACGACCC3’
C1GALT1 reverse primer 5’CATCTCCCCAGTG
CTAAGTCTTCAATG3’
After 5 minutes at 95°C, 40 cycles were performed: 15
seconds denaturation at 94°C, 30 seconds annealing at
60°C, 30 seconds extension at 72°C and fluorescence
detection at 78°C. A melting curve fluorescence analysis
was performed on each sample once the amplification
cycles were completed to verify that a single product
had been amplified. Each sample was normalized to the
Table 2 Sera reacting with MUC1 glycoforms when screened against arrays displaying glycoforms shown in Figure 1B
Sera from patients with benign breast
disease used to define cut-off
Sera from age-matched healthy females
used to define cut-off
P < 0.0001 P = 0.0007
Breast cancer n (%) Benign disease n (%) Breast cancer n (%) Healthy females n (%)
negative 271 (69) 97 (90) 272 (69) 85 (86)
positive
1 124 (31) 11 (10) 123 (31) 14 (14)
strong positive
2 97 (24) 8 (7) 80 (20) 7 (7)
1Sera was defined as positive if it was two standard deviations or higher than the mean fluorescence for at least one feature.
2 Sera was defined as strong positive if four standard deviations or higher than the mean fluorescence for at least one feature
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tions were performed in triplicate.
Results
Sera from breast cancer patients contain autoantibodies
to multiple MUC1 glycoforms
In our previous work screening for autoantibodies to
MUC1 glycoforms, we used enzymatic solution synthesis
of glycopeptides based on three tandem repeats of MUC1
and the sera were commercially obtained [13]. Using
these arrays we confirmed that autoantibodies to MUC1
carrying the truncated O-linked glycans core3, STn - and
to a lesser extent Tn - were indeed present in a propor-
tion of the sera (54/198) from the early stage breast can-
cer patients to be analysed here (data not shown).
To examine the specificity of these antibodies in more
detail, and to test if glycopeptides based on a single tan-
dem repeat could be used for antibody detection, we
used solid-phase glycopeptide synthesis with on-chip
microarray purification [19] to construct a micro-array
of glycopeptides based on a single 20 amino acid tan-
dem repeat of MUC1 (MUC1a, see Figure 1). Thirty-
one Tn MUC1 glycopeptides, carrying each glycan at
different sites were chemically synthesized and extended
on-chip with glycosyltransferases to form core3 and STn
MUC1 glycopeptides (see Figure 2, [19] and Materials
and methods).
Analysis with these arrays of five of the sera from
early breast cancer patients found to be positive on the
60mer arrays confirmed that IgG autoantibodies could
be detected to MUC1 carrying Tn, core3 and STn when
using only a single tandem repeat. Figure 2 shows three
examples of the profile of autoantibodies documented in
the patients’ sera. For clarity in presentation the reactiv-
ity with only seven informative MUC1 glycopeptides is
shown. Autoantibodies could be identified in the sera
from an individual patient that recognised several glyco-
forms carried on MUC1a, that is, Tn, STn and core3
(patient A), or that reacted with one particular glyco-
form (sera from patients B and C). Moreover, even
though the same glycoform could be recognised by sera
from patients A and B (core3MUC1) or from patients A
and C (STnMUC1), the site carrying the glycan recog-
nised by the antibodies was different. Therefore, the on-
chip glycosylation is a rapid approach to reveal detailed
autoantibody signatures to glycopeptides of MUC1.
Screening of sera from a large cohort of early stage
breast cancer patients, patients with benign breast
disease, and healthy women
To produce sufficient quantities of glycopeptides
required to screen large numbers of sera it was necessary
to use a combination of chemical synthesis coupled with
chain extension in solution with glycosyltransferases. To
expedite the chemical synthesis of glycopeptides using
Tn or core3 building blocks two MUC1 20mer glycopep-
tides (MUC1a and MUC1b) were designed with a 10mer
overlap. MUC1a and MUC1b carrying Tn in three posi-
tions or core3 in two positions were chemically synthe-
sized (see Figure 1B) and for technical reasons the
glycopeptide carrying core3 at the PDTRP threonine
position was synthesized separately. The TnMUC1 and
core3MUC1 glycopeptides were enzymatically extended
in solution to produce either the STn or ST glycoforms
or the extended core3 structures respectively (see Table
S1 in Additional file 1 for full list). These 20mer glyco-
peptides, and for comparison with the previous pilot
study [13] a 60mer carrying core3, were printed onto
slides and the arrays validated by the use of lectins and
monoclonal antibodies (see Figure S1 in Additional file
2). The 60mer carrying core3 gave very similar results to
the 20mer carrying core3 (see Figure S2 in Additional
file 3). However, the use of the smaller glycopeptides
allowed the synthesis of a wider selection of MUC1
glycoforms.
These arrays were used to screen 395 sera taken
before surgery from breast cancer patients with Stage I
or Stage II disease (P-series). Clinical parameters for
these patients are listed in Table 1 and their average age
was 59.9. The availability of extended clinical follow-up
Table 3 Autoantibodies in cancer patient sera to MUC1 glycoforms correlate with age when sera were taken
Sera from patients with benign breast disease used to
define cut-off
Sera from age-matched healthy females used to define
cut-off
All positives
1 Strong positives
2 All positives Strong positives
P = 0.001 P = 0.001 P = 0.007 P = 0.003
Age sera taken N n (%) n (%) n (%) n (%)
<50 63
3 7 (11) 3 (5) 14 (22) 5 (8)
50 to 59 132 33 (25) 27 (20) 31 (24) 21 (16)
60 to 69 136 57 (42) 46 (34) 51 (38) 39 (29)
70+ 64 27 (42) 21 (33) 27 (42) 15 (23)
1 Sera were defined as all positive if two standard deviations or higher than the mean fluorescence for at least one feature.
2 Sera was defined as strong positive if four standard deviations or higher than the mean fluorescence for at least one feature.
3 Total number in age group
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the expected correlations with the standard parameters
for predicting prognosis (lymph node involvement,
grade, tumour size and age at diagnosis, see Figure S3 in
Additional file 4). Sera from 108 patients with benign
breast disease who attended Guy’sH o s p i t a ld u r i n ga
similar period were also analysed. In order to age-match
the controls with the breast cancer patients, sera of age-
ranged matched healthy females (n = 99, average age 54.7
years) who had not developed any form of cancer 25 to
30 years after donation were also included in the analysis.
The MUC1a and MUC1b glycopeptides giving infor-
mative results are listed in Figure 1B. Figure 3 shows
the reactivity of the screened sera on the combined
Figure 3 Reactivity of auto-antibodies in sera with MUC1 glycoforms. A, dot blot showing the reactivity of auto-antibodies present in sera
from breast cancer patients, red crosses; patients with benign breast disease, blue circles; and healthy females aged ranged matched to the
cancer patients, green circles. Bars indicate the position for 2x the standard deviation of the mean of the benign serum values, (solid bar) or the
aged matched normal values, (dotted bar). Glycopeptides are defined in figure 1B. Inserts show the reactivity of autoantibodies in the sera of
breast cancer patients with MUC1a and b carrying STn (left insert) and MUC1a and b carrying core3 (right insert). Each red line represents an
individual serum sample. B, heat maps of the reactivity of autoantibodies in sera to glycopeptides 1 to 10 defined in figure 1B. Breast Cancer
Cont, breast cancer sera continued.
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Page 9 of 16MUC1a and MUC1b individual glycan features both as
a dot blot and a heat map, the latter allowing visualisa-
tion of the reactivity of each serum sample. The dot
blot (Figure 3A) shows that the highest frequency of
autoantibodies in the cancer patients’ sera is to the
core3 based and STn MUC1 glycopeptides and these
also gave the strongest signals. Importantly, reactivity
to the haptens core3 or STn linked to threonine, or to
the unglycosylated MUC1 was weak and found in only
a few patients thus demonstrating that the strongly
binding autoantibodies were largely directed to epi-
topes determined by both the glycan and the core
peptide.
The autoantibodies in breast cancer sera that reacted
with STnMUC1 reacted either with the STnMUC1a or
t h eS T n M U C 1 bb u tn o tw i t hb o t h( s e ei n s e r ti nF i g u r e
3A). In addition, the majority of sera containing antibo-
dies to core3 MUC1 showed reactivity with core3
MUC1a, with only four sera showing reactivity with
MUC1b (see right insert in Figure 3A). Fewer and
weaker responses were seen to ST and Tn MUC1.
Expression of b3GnT6 by breast carcinomas
The core3 structure is synthesized by the enzyme core3
b3-N-acetylglucosamine transferase which is encoded
by the b3GNT6 gene. This glycosyltransferase is not
expressed in the normal mammary gland and it has not
been found in breast carcinomas [23]. We, therefore,
looked by RT-qPCR at the expression of b3GNT6 in 58
Stage 1 and Stage 2 breast carcinomas (see Figure S4 in
Additional file 5). As expected, normal colon showed rea-
sonable levels of the transcript. However, in only 3 out of
58 breast carcinoma samples was a b3GNT6 transcript
detectable and these were at least 100-fold lower than the
glycosyltransferase, C1GALT1, that competes for the
same sugar substrate to form core 1 (T). This observation
together with published data, presents compelling evi-
dence that core3 is not expressed by breast carcinomas
suggesting that the MUC1-core3 glycan on the microar-
ray may be acting as an epitope mimic.
Quantitative analysis of the screening assay to define
serum reactivity
Table 2 shows the number and percentage of positive
(defined as two standard deviations above the means)
and strongly positive (defined as four standard deviation
above the means) with one or more of the glycopeptides
described in Figure 1B for the breast cancer patients,
patients with benign breast disease and healthy controls,
using either the benign sera or the sera from healthy
females to define the cut offs.
Thirty-one percent of the breast cancer patients had
IgG autoantibodies to the glycopeptides whether the sera
from patients with benign breast disease or sera from
healthy women were used as controls. Both control
cohorts showed a 7% rate of strongly positive sera, and
using the cut off from data obtained from sera from
patients with benign disease, 24% of the cancer patient
sera were strongly positive. This was reduced to 20%
when the sera from healthy females (who did not develop
cancer) were used for establishing the cut off. We found
a highly significant correlation of the presence of antibo-
dies with age in the cancer patients, which was observed
whether the cut-off used was from the benign or the
more closely aged matched controls (see Table 3). There-
fore this difference of 20% versus 24% may be due the
difference in age of the control cohorts.
ROC curves, shown in Figure 4, were constructed for
each of the nine features (see ‘Materials and methods’)
using either the benign serum values to provide the cut
off or the values from the age matched healthy indivi-
duals. Giving an equal weight to all features (shown in
pale grey lines) we formed a combination (generalised
ROC curve) to give a single curve (red line). Figure 4
shows that this gave an area under the curve of 0.777
and 0.730 when using the benign sera or sera from
healthy females to define cut-offs respectively. Using sera
from benign patients to define cut-offs, the generalised
ROC curve showed an improvement over the curves of
the individual features. When looking at the dot plots in
Figure 3A it is obvious that some glycoforms contribute
more information and the STn and core3 glycoforms give
both high positive breast cancers along with a low posi-
tive benign. Using these criteria, we constructed a ROC
curve of this subset of glycoforms (combinational subset
defined in Figure 1B) and this is shown by the solid black
line in Figure 4. The area under this ROC curve is close
to the ROC curve area for the combination of all fea-
tures. When the generalised and combinational ROC
curves were applied to the samples using sera from the
healthy women as the controls these curves were not as
informative as some of the individual features (see Figure
4B) but in these latter cases, only a small number of sera
were positive (see Figure 3A).
Prognostic significance of autoantibodies to MUC1
glycoforms
To investigate correlations with clinical parameters we
used the healthy female control sera to define the cut-offs
as they were more closely age matched. We used two
standard deviations above the mean for each glycopeptide
to define as all positives and four standard deviations
above the mean to define strong positives. The presence of
IgG autoantibodies was then compared to a series of clini-
cal parameters including occurrence of metastases within
15 years, grade, lymph node involvement, tumour size, ER
positivity, parity and age. When IgG autoantibodies to all
the glycoforms screened were analysed there was a
Blixt et al. Breast Cancer Research 2011, 13:R25
http://breast-cancer-research.com/content/13/2/R25
Page 10 of 16correlation with tumour grade but no other parameters
(data not shown). However, using the subset defined in
Figure 1B and Figure 4, Table 4 shows that the highly sig-
nificant correlation with age remained (P = 0.001) and a
significant correlation was observed with tumour grade
when the strong positives were analysed (P = 0.016).
Moreover, autoantibodies to this combinational subset
were associated with a lower incidence of metastasis with
a follow-up of 15 years (see Table 4).
The metastasis-free survival was plotted for the sera
containing IgG autoantibodies to glycopeptides in
the combinational subset compared to negative sera.
Figure 5 shows that there was a separation of the curves
and Log Rank testing gave a P-value of 0.081 for all
positives and 0.032 for the strong positives. However,
when using Cox regression analysis adjusted for age,
nodal status, grade and tumour size, this association was
lost (P = 0.834, data not shown). This suggests that the
presence of autoantibodies is not an independent vari-
able but rather reflects the clinical condition of a patient
with early disease. There was also no significant associa-
tion of strongly positive sera with overall survival to 15
 
 
  Sera from patients with 
benign breast disease used 
to define cut-off 
  Sera from age-matched 
healthy females used to 
define cut-off 
  Mean + 2SD  Mean + 4SD    Mean + 2SD  Mean + 4SD 
Compound Area  Sens 
(%) 
Spec 
(%) 
Sens 
(%) 
Spec 
(%) 
Area Sens 
(%) 
Spec 
(%) 
Sens 
(%) 
Spec 
(%) 
MUC1  0.726 2.03  97.22 1.01  99.07 0.788 11.14 96.97 2.78  98.99 
TnMUC1  0.695  2.03 99.07  0.76 99.07  0.744  5.57 97.98  3.29  98.99 
STn  MUC1*  0.727 11.14 97.22 7.59  98.15 0.736 9.87  97.98 6.84  97.98 
STMUC1  0.693  3.04 99.07  2.53 99.07  0.699  9.87 95.96  6.33  98.99 
C3MUC1*  0.748 21.27 94.44 17.97 98.15 0.693 10.13 93.94 6.08  96.97 
C3S6MUC1*  0.714 14.18 96.30 10.13 97.22 0.639 4.05  96.97 2.28  98.99 
LeCC3MUC1* 0.755  8.10  96.30  6.08  97.22 0.692 7.59  96.97 5.32  97.98 
SLeCC3MUC1  0.722  3.29 98.15  3.04 98.15  0.713  6.08 98.99  3.54  98.99 
LeCC3S6MUC1* 0.773 6.58  98.15 2.78  98.15 0.784 6.08  98.99 2.78  98.99 
Comb  0.777 10.63 97.22 4.81  99.07 0.730 10.63 95.96 4.81  97.98 
Comb Subset 
C3 + STn (*) 
0.776 10.38 97.22 4.56  100.0 0.726 10.38 95.96 4.56  97.98 
C3Thr  0.689  4.30 96.30  2.28 98.15  0.688  1.77 96.97  1.27  97.98 
*MUC1 glycans in the Combination subset 
A  B 
Figure 4 Receiver operating characteristic analysis of individual and combinations of features. A, sera from patients with benign breast disease
defines cut-offs; B, sera from healthy females defines cut-offs. Pale dotted grey lines represent individual features, solid red line represent the
combination of all the features and solid black line represents the combinational subset defined in Table by * and Figure 1B by *. The table shows ROC
curve area and sensitivity/specificity data for breast cancer sera on each MUC1 glycan, combination of all MUC1 glycans and a combination subset.
Blixt et al. Breast Cancer Research 2011, 13:R25
http://breast-cancer-research.com/content/13/2/R25
Page 11 of 16years in either univariate, see Figure 5C, or multivariate
analysis (P = 0.601, data not shown).
Discussion
T h ee f f o r t st od i a g n o s ec a n c e rb yt h eu s eo fs e r u m
assays have met with limited success, partly because the
disease is heterogeneous at both causative and host
response levels. The changes in O-linked glycosylation
that occur in cancer [16,23] result in the production of
cancer-associated glycoforms of cancer-associated glyco-
proteins, which are antigenically distinct and are able to
induce IgG autoantibodies [13,24,25]. By taking into
account these modifications, the specificity of diagnostic
markers might be expected to be improved, as they
reflect both the patho-physiology of the disease and the
hosts’ response. Using novel micro-arrays carrying dif-
ferent glycoforms of MUC1 we have demonstrated the
presence of autoantibodies in the sera of a proportion of
breast cancer patients that recognise MUC1 carrying
specific O-linked glycans. The difference in the percen-
tage of sera strongly positive for the antibodies in cancer
patients’ sera versus sera from patients with benign dis-
ease or from healthy individuals who never developed
cancer is highly significant.
Unglycosylated MUC1, or undefined glycoforms of
MUC1, has been used in other ELISA based assays for
detecting antibodies in sera from cancer patients
[1-3,12]. However, using the microarray assay described
here, the antibody response to un-glycosylated MUC1
w a sv e r yw e a ka n do n l ys e e ni nav e r ys m a l ln u m b e ro f
patients (see Figure 3A). In contrast, IgG autoantibodies
to defined MUC1 glycoforms were found in 31% of
Stage I and II breast cancer patients. Importantly, ele-
vated levels of circulating MUC1 antigen (CA15-3) was
Table 4 Correlation of sera autoantibodies to MUC1 glycopeptide combinational subset with clinical variables
Autoantibody positive Strong autoantibody positive
A
N
B % positive N
A,B % positive
Age at diagnosis P = 0.001
C P < 0.001
<50 63 5 61 2
50 to 59 132 14 125 9
60 to 69 136 27 129 23
70+ 64 27 57 18
Stage P = 0.215 P = 0.104
Node negative 200 22 189 17
Node positive 193 17 181 11
Positive nodes P = 0.195 P = 0.219
0 200 22 189 17
1 to 3 124 19 114 12
4+ 69 12 67 9
Clin tumour size P = 0.483 P = 0.306
0 to 2 cm 133 19 129 16
2.1 to 4 cm 176 20 162 13
>4 cm 74 14 70 9
Tumour grade/type P = 0.165 P = 0.016
ID Grade I 37 30 35 26
ID Grade II + I Lob 195 19 187 15
ID Grade III 120 16 109 7
ER Status P = 0.883 P = 0.183
ER negative 131 18 120 11
ER positive 211 19 204 16
Parity P = 0.730 P = 0.436
0 children 87 23 82 18
1 to 2 children 171 19 164 16
3+ children 96 19 88 11
Metastases to 15 yrs P = 0.058 P = 0.028
No 238 22 237 17
Yes 155 14 133 9
A Weak positives excluded.
B Total number in that group for the variable.
C Using Chi-squared test for equality of distributionsBold text indicates a significant correlation.
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Page 12 of 16Figure 5 Breast cancer patients with autoantibodies to MUC1 glycopeptide combinational subset show increased time to metastasis.
A, metastasis free survival with patients with autoantibodies versus no auto-antibodies (P = 0.08). B, metastasis free survival of patients with
strong autoantibodies versus no antibodies (P = 0.032). C, overall survival of patients with strong autoantibodies versus no antibodies. Thick lines
indicate no auto-antibodies in sera. Dotted lines indicate autoantibodies. Vertical dashes indicate censored events.
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Page 13 of 16not detected in these serum samples from early stage
patients. In contrast, in late stage patients, where MUC1
antigen can be detected in sera, IgG autoantibodies were
not detected (data not shown). This emphasises the
importance of the autoantibody assay in early breast
cancer when the antigen itself cannot be detected and
the induction of autoantibodies represents an amplifica-
tion of the antigenic signal.
Autoantibodies were detected to MUC1 carrying core3
based glycans and STn, with fewer responses seen to Tn
and ST glycoforms. The STn glycan is relatively tumour
specific, but expression of this glycan is seen in only 25
to 30% of breast cancers, which could explain the lower
percentage of sera showing IgG autoantibodies to
STnMUC1 compared to other cancers such as colo-rec-
tal [13,19]. Although the ST glycoform is the main
MUC1 glycoform found in sera of advanced breast can-
cer patients [26], fewer and weaker responses were seen
to STMUC1. ST is also found on other serum proteins,
therefore, tolerance might be expected to be operative.
The dominance of antibodies to core3MUC1 in the
breast cancer sera is surprising. The enzyme catalysing
the addition of GlcNAc to GalNAc to produce core3
(b3GNT6) is generally only expressed in the cells of the
gastrointestinal (GI) tract and it is dramatically downre-
gulated in colon cancer [27,28]. We found that the
b3GNT6 transcript could only be detected in 3 of 58
breast carcinomas, and even then the level was at least
100-fold lower than the competing glycosyltransferase,
C1GALT1. Moreover, core3 structures have not been
found in normal breast or breast carcinomas [23]. While
clearly the autoantibodies recognise core-3 structures on
MUC1 (but not the core3-threonine), it is possible that
the antibodies were induced to a structure that is
mimicked by MUC1 carrying core-3.
Our data (Table 3) show that the presence of autoan-
tibodies in the breast cancer patients is highly correlated
with age, emphasising the importance of using aged-
matched controls for any autoantibody study. The
increase of autoantibodies with age has been reported
for both mice and man [29]. Also, in a study by Pinheiro
et al., measuring antibodies to unglycosylated MUC1 by
ELISA in sera collected in the Nurses Health Studies, an
association with age was noted in women with antibo-
dies who went on to develop ovarian cancer [12]. The
increased specificity and sensitivity of the assay when
using sera from patients with benign breast disease to
determine cut-offs almost certainly reflects the younger
age of the patients with benign disease. However, the
correlation with age that we observed was maintained
when the data were analysed using sera from the age
range matched healthy females.
The availability of ideal control sera for use in retro-
spective studies can be a problem. The sera from patients
with benign breast disease were collected at the same site
and at around the same time as the cancer patients, thus
reflecting the same population for both cohorts. However,
the age demographics of benign breast disease results in
the mean age of these patients being significantly younger
than the breast cancer patients. The healthy control sera
used were taken in the 1970s from healthy females living
on the island of Guernsey [22] and allowed not only clo-
ser age matching, but extensive follow-up, although the
ethnicity of the Guernsey and P-series populations may
not be identical. Nevertheless, the availability of extensive
follow-up allowed for the selection of sera from Guernsey
women who had not developed any form of cancer for
25 to 30 years after blood donation. It should be noted
that sera from all three cohorts were stored under identi-
cal conditions and for similar periods of time. Using sera
from healthy women to determine cut-off points we
found a significant association of the presence of autoan-
tibodies to the combinational subset with increased time
to metastasis (see Figure 5). Although this was not an
independent variable, it should be noted that when the
presence of autoantibodies to any of the other glycopep-
tides screened were analysed, no such significant associa-
tion was observed (data not shown). This suggests that
autoantibodies to the combinational subset could play a
role in disease progression.
An important question which should be addressed is
how long before clinical symptoms develop can IgG auto-
antibodies to aberrant glycoforms of MUC1 be detected?
We have anecdotal evidence that the antibodies may
appear early since one of the patients who had benign
disease and high levels of IgG autoantibodies to MUC1
glycopeptides, developed breast cancer five years later.
However, antibodies to the subset of MUC1 glycopep-
tides were found in a number of the control sera taken
from the cohort of women on Guernsey where no cancer
developed during 25 to 30 years of follow-up. The possi-
bility arises that these antibodies may be functional in
suppressing tumour development, as well as progression.
This may be particularly true for the anti-STn-MUC anti-
bodies (found in 2% of controls) as this glycoform is truly
cancer specific and therefore the presence of antibodies
should indicate the presence of tumour, albeit on a micro
scale. However, as MUC1 and core3 are expressed in the
colon there is the possibility that antibodies to MUC1-
core3 may be induced during an inflammatory response
occurring in the colon resulting in expression of shorter
glycans [30]. However, following up individuals who have
antibodies would not be an overwhelming procedure as it
merely involves taking blood and screening with the
arrays for antibody levels- possibly in parallel with mam-
mography screening.
In searching for a simple, cost effective and non-inva-
sive screening assay that could pick up breast
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Page 14 of 16malignancy in its early stages it should be noted that the
MUC1 mucin is expressed by other carcinomas such as
ovarian and lung, and IgG autoantibodies to MUC1 car-
rying core3 or STn glycans have been detected in sera
from patients with these cancers [13]. Thus, an assay
based solely on aberrant glycoforms of MUC1 applied to
sera from individuals without clinical symptoms would
not necessarily distinguish between the different carci-
nomas. To extend this work we are using our on-chip
technology and other glycopeptide platforms for
high-throughput screening and discovery of disease-
associated autoantibody glycopeptide epitopes in other
proteins with more organ specific expression patterns.
Conclusions
Whereas the serum assay (CA15.3) used for detecting the
cancer associated MUC1 antigen in breast cancer patient
serum does not detect elevated antigen in early stage
breast cancer, autoantibodies to specific tumour-asso-
ciated glycoforms of MUC1 can be detected in sera from
Stage I and Stage II breast cancer patients. The difference
in the percentage of sera strongly positive for the antibo-
dies in cancer patient sera versus sera from patients with
benign disease or from healthy individuals who never
developed cancer is highly significant. Follow-up of
patients with benign breast disease with sera with high
levels of autoantibodies may be appropriate. The lower
incidence of metastases and delay in development of
metastases in patients with high levels of antibodies to a
subset of the glycoforms, suggests that the antibodies
may play a role in inhibiting the progression of disease.
Administration of antibodies with these specificities is,
therefore, a possible therapeutic strategy. This would be
particularly appropriate for breast cancer patients with
STn positive cancers (25 to 30% of breast cancer patients)
as the STnMUC1 glycoform is truly tumour specific.
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